SESSION TITLE: Pulmonary Vascular Disease II
SESSION TYPE: Original Investigation Poster
PRESENTED ON: Wednesday, October 26, 2016 at 01:30 PM - 02:30 PM
PURPOSE: Pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) are rare, progressive diseases characterized by increases in pulmonary artery pressure (PAP) and pulmonary vascular resistance with high morbidity and mortality. Despite advances in treatment and patient outcomes, recent studies have shown common diagnostic errors and an underutilization of consensus treatment guidelines. The Pulmonary Hypertension Association (PHA) launched the PH Care Centers (PHCC) initiative to identify centers with a focused interest in PH and to better understand adherence and barriers to consensus best practices.